

Hwanhee Hong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4184801/publications.pdf>

Version: 2024-02-01

39
papers

1,448
citations

393982

19
h-index

344852

36
g-index

41
all docs

41
docs citations

41
times ranked

2162
citing authors

#	ARTICLE	IF	CITATIONS
1	A note on semiparametric efficient generalization of causal effects from randomized trials to target populations. <i>Communications in Statistics - Theory and Methods</i> , 2023, 52, 5767-5798.	0.6	4
2	Comparing the performance of statistical methods that generalize effect estimates from randomized controlled trials to much larger target populations. <i>Communications in Statistics Part B: Simulation and Computation</i> , 2022, 51, 4326-4348.	0.6	3
3	Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2022, 114, 191-202.	3.0	12
4	Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis. <i>Value in Health</i> , 2022, 25, 796-802.	0.1	6
5	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. <i>Circulation</i> , 2022, 145, 242-255.	1.6	118
6	Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges. <i>Clinical Trials</i> , 2022, 19, 561-572.	0.7	2
7	Effect of <i>Haemophilus influenzae</i> Type b and 13-Valent Pneumococcal Conjugate Vaccines on Childhood Pneumonia Hospitalizations and Deaths in Botswana. <i>Clinical Infectious Diseases</i> , 2021, 73, e410-e416.	2.9	11
8	Meta-analysis of rare adverse events in randomized clinical trials: Bayesian and frequentist methods. <i>Clinical Trials</i> , 2021, 18, 3-16.	0.7	16
9	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale. <i>American Heart Journal</i> , 2021, 233, 48-58.	1.2	11
10	Aspiration thrombectomy in ST-Elevation myocardial infarction: Further insights from a network meta-analysis of randomized trials. <i>Indian Heart Journal</i> , 2021, 73, 161-168.	0.2	0
11	Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 412.	3.4	63
12	Restoring invisible and abandoned trials of gabapentin for neuropathic pain: a clinical and methodological investigation. <i>BMJ Open</i> , 2021, 11, e047785.	0.8	3
13	Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer—Reply. <i>JAMA Oncology</i> , 2021, 7, 1069.	3.4	0
14	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 582.	3.0	71
15	Microbiology of Bloodstream Infections in Children After Hematopoietic Stem Cell Transplantation: A Single-Center Experience Over Two Decades (1997–2017). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa465.	0.4	8
16	Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events. <i>Trials</i> , 2019, 20, 553.	0.7	23
17	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2019, 4, 747.	3.0	198
18	Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 11-19.	2.4	24

#	ARTICLE	IF	CITATIONS
19	Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 20-27.	2.4	34
20	Keloid Excision and Adjuvant Treatments. <i>Annals of Plastic Surgery</i> , 2019, 83, 154-162.	0.5	21
21	Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot. <i>European Heart Journal</i> , 2019, 40, 3768-3770.	1.0	11
22	Propensity Score-Based Estimators With Multiple Error-Prone Covariates. <i>American Journal of Epidemiology</i> , 2019, 188, 222-230.	1.6	7
23	Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, e1609.	1.1	7
24	Power and Commensurate Priors for Synthesizing Aggregate and Individual Patient Level Data in Network Meta-Analysis. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2018, 67, 1047-1069.	0.5	10
25	Caveat emptor: the combined effects of multiplicity and selective reporting. <i>Trials</i> , 2018, 19, 497.	0.7	18
26	Bayesian hierarchical models for network meta-analysis incorporating nonignorable missingness. <i>Statistical Methods in Medical Research</i> , 2017, 26, 2227-2243.	0.7	28
27	Multiple outcomes and analyses in clinical trials create challenges for interpretation and research synthesis. <i>Journal of Clinical Epidemiology</i> , 2017, 86, 39-50.	2.4	97
28	Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 95-110.	2.4	83
29	Bayesian Approach for Addressing Differential Covariate Measurement Error in Propensity Score Methods. <i>Psychometrika</i> , 2017, 82, 1078-1096.	1.2	7
30	Reply. <i>Ophthalmology</i> , 2016, 123, e66.	2.5	1
31	A Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons. <i>Research Synthesis Methods</i> , 2016, 7, 6-22.	4.2	81
32	Rejoinder to the discussion of "a Bayesian missing data framework for generalized multiple outcome mixed treatment comparisons," by S. Dias and A. E. Ades. <i>Research Synthesis Methods</i> , 2016, 7, 29-33.	4.2	34
33	Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma. <i>Ophthalmology</i> , 2016, 123, 129-140.	2.5	217
34	Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review. <i>Systematic Reviews</i> , 2015, 4, 143.	2.5	15
35	Incorporation of individual-patient data in network meta-analysis for multiple continuous endpoints, with application to diabetes treatment. <i>Statistics in Medicine</i> , 2015, 34, 2794-2819.	0.8	27
36	Longitudinal Changes in Nursing Home Resident-Reported Quality of Life. <i>Research on Aging</i> , 2015, 37, 555-580.	0.9	37

#	ARTICLE	IF	CITATIONS
37	Guidance on the implementation and reporting of a drug safety Bayesian network meta-analysis. <i>Pharmaceutical Statistics</i> , 2014, 13, 55-70.	0.7	24
38	Comparing Bayesian and Frequentist Approaches for Multiple Outcome Mixed Treatment Comparisons. <i>Medical Decision Making</i> , 2013, 33, 702-714.	1.2	69
39	Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. <i>Aids</i> , 2011, 25, 1471-1479.	1.0	47